AP
APTO

Atlas Principals’s Aptose Biosciences, Inc. APTO Stock Holding History

Atlas Principals’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-878
Closed -$2.37M – 49
2020
Q3 		$2.37M Buy
878
+322
+58% +$803K 1.19% 25
2020
Q2 		$1.58M Buy
556
+334
+150% +$1.08M 1.17% 26
2020
Q1 		$594K Buy
+222
New +$662K 0.56% 31

Other funds holding APTO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Atlas Principals's APTO Position: Q4 2020 in Review

Atlas Principals sold out of Aptose Biosciences, Inc. (APTO) in Q4 2020, closing a stake of 878 shares — an estimated $2.37M sold.

Atlas Principals first reported a position in APTO in Q1 2020 and held it in 3 quarters. The position peaked at $2.37M in Q3 2020. 65 funds tracked by Wall St. Rank hold APTO as of Q4 2020.

  • Atlas Principals reported no remaining Aptose Biosciences, Inc. position as of Q4 2020 after selling out during the quarter.
  • Atlas Principals sold 878 Aptose Biosciences, Inc. shares in Q4 2020, an estimated $2.37M.
  • Atlas Principals first reported a position in Aptose Biosciences, Inc. in Q1 2020 and held it in 3 quarters.
  • Atlas Principals's Aptose Biosciences, Inc. position peaked at $2.37M in Q3 2020.
  • 65 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q4 2020.

Based on Atlas Principals's 13F filing for Q4 2020, filed 16 Feb 2021.